Roche stock price hits a 6-month low as drug sales miss estimates

Shares of Roche GS (SIX: ROG) fell 3.49% today after the Swiss drugmaker reported lower-than-expected drug sales.  Fundamental analysis: Covid-19 helping sales Roche said that increased demand for coronavirus tests helped elevate its Q3 revenues and compensate for plummeting drug sales.  Thomas Schinecker, head of Roche’s diagnostics business said a surge in new coronavirus cases were fueling demand for the low-cost antigen tests as the supply PCR tests is still low. In spite of the fact that Roche’s antigen tests, which cost around $5 apiece, are less accurate than PCR tests, Schinecker claimed they proved useful in a number of